Cargando…
A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients
BACKGROUND: Gene signatures measured in a biopsy have been proposed as hypoxia biomarkers in prostate cancer. We assessed a previously developed signature, and aimed to determine its relationship to hypoxia and its heterogeneity within the dominant (index) lesion of prostate cancer. METHODS: The 32-...
Autores principales: | Salberg, Unn Beate, Skingen, Vilde Eide, Fjeldbo, Christina Sæten, Hompland, Tord, Ragnum, Harald Bull, Vlatkovic, Ljiljana, Hole, Knut Håkon, Seierstad, Therese, Lyng, Heidi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296675/ https://www.ncbi.nlm.nih.gov/pubmed/35332267 http://dx.doi.org/10.1038/s41416-022-01782-x |
Ejemplares similares
-
Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter
por: Hompland, Tord, et al.
Publicado: (2021) -
miR‐200a/b/‐429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer
por: Nilsen, Anja, et al.
Publicado: (2022) -
Comparison of time curves from dynamic (18)F-fluciclovine positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging for primary prostate carcinomas
por: Tulipan, Andreas Julius, et al.
Publicado: (2018) -
The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
por: Ragnum, H B, et al.
Publicado: (2015) -
Combining imaging- and gene-based hypoxia biomarkers in cervical cancer improves prediction of chemoradiotherapy failure independent of intratumour heterogeneity
por: Fjeldbo, Christina S., et al.
Publicado: (2020)